Use of Light-Degradable Aliphatic Polycarbonate Nanoparticles As Drug Carrier for Photosensitizer,Biomacromolecules

当前位置： X-MOL 学术 › Biomacromolecules › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Use of Light-Degradable Aliphatic Polycarbonate Nanoparticles As Drug Carrier for Photosensitizer
Biomacromolecules ( IF 5.5 ) Pub Date : 2018-11-15 00:00:00 , DOI: 10.1021/acs.biomac.8b01446
Jingjiang Sun _{1,

2} , Wolfgang Birnbaum ₁ , Juliane Anderski ₃ , Marie-Theres Picker ₁ , Dennis Mulac ₃ , Klaus Langer ₃ , Dirk Kuckling ₁

Affiliation

Aliphatic poly(carbonate)s (APCs) with rapid and controlled degradation upon specific stimulation have great advantages for a variety of biomedical and pharmaceutical applications. In the present work, we reported a new poly(trimethylene carbonate) (PTMC)-based copolymer containing multiple 4,5-dimethoxy-2-nitrobenzyl photo cleavable groups as pendent chains. The six-membered light-responsive cyclic carbonate monomer (LrM) was first prepared from 2-(hydroxymethyl)-2-methylpropane-1,3-diol and 4,5-dimethoxy-2-nitrobenzyl alcohol and then copolymerized with trimethylene carbonate (TMC) by 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) catalyzed ring-opening polymerization (ROP) to afford the light-responsive polycarbonate (LrPC). The light-triggered decomposition of LrM and LrPC was studied by NMR, UV/vis spectroscopy, and size exclusion chromatography (SEC), as well as ESI-ToF mass spectrometry. Stable monodisperse nanoparticles with hydrodynamic diameter of 100 nm could be formulated from 25% LrPC and 75% poly(lactide-co-glycolide) (PLGA) and applied for the encapsulation of temoporfin. Upon irradiation with UV light these particles displayed a significant decrease of the particle countrate and increased the release rate of temoporfin in comparison to standard PLGA nanoparticles. This work demonstrated that a combination of encapsulation of photosensitizer and light degradation using light-responsive polymers is suitable to enhance photodynamic therapy (PDT).

中文翻译：

可光降解的脂肪族聚碳酸酯纳米粒子作为光敏剂的药物载体的用途

在特定刺激下具有快速可控降解的脂肪族聚碳酸酯（APC）对于多种生物医学和制药应用具有巨大优势。在目前的工作中，我们报道了一种新型的聚碳酸三亚甲基酯（PTMC）基共聚物，其中含有多个4,5-二甲氧基-2-硝基苄基光可裂解基团作为侧链。首先由2-（羟甲基）-2-甲基丙烷-1,3-二醇和4,5-二甲氧基-2-硝基苄醇制备六元光响应性环状碳酸酯单体（LrM），然后将其与碳酸三亚甲基酯（通过1，8-二氮杂双环（5.4.0）十一碳-7-烯（DBU）催化的开环聚合（ROP），得到光响应性聚碳酸酯（LrPC）。LrM的光触发分解和LRPC通过NMR，UV / vis光谱研究，和大小排阻层析（SEC），以及ESI-TOF质谱。可以用25％LrPC和75％聚（丙交酯-共-乙交酯）（PLGA）配制具有100 nm流体力学直径的稳定单分散纳米颗粒，并将其用于替莫泊芬的封装。与标准PLGA纳米粒子相比，在用紫外线照射后，这些粒子显示出粒子计数率显着降低，并增加了替莫泊芬的释放速率。这项工作表明，使用光响应性聚合物将光敏剂封装和光降解相结合，可以增强光动力疗法（PDT）。

更新日期：2018-11-15

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11